Gastrointestinal intolerances are common, and patients should be instructed on how to mitigate these events (e.g., take metformin with a meal) to improve tolerability of treatment
Switching to a daily tablet removes the need to inject
Changing our societys perception of obesity is the key here
One of the most consistent things people report on semaglutide is a marked drop in appetite and in the intrusive, repetitive thoughts about food that many describe as food noise. By reinforcing the bodys natural satiety signaling, it becomes easier to recognize fullness, stop eating sooner, and go longer between meals without feeling deprived
The dedicated FLOW trial of subcutaneous semaglutide in T2D-related CKD showed a 24% reduction in the composite of major kidney disease events (HR 0.76, 95% CI 0.660.88) and significant reductions in cardiovascular outcomes [22], supporting GLP-1RA therapy as an evidence-based addition for cardiorenal protection in this population